



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/663,181	09/15/2003	Steven Z. Wu	50623.334	1431
7590	10/04/2007		EXAMINER	
Cameron Kerrigan Squire, Sanders & Dempsey L.L.P. Suite 300 One Maritime Plaza San Francisco, CA 94111-3492			SHEIKH, HUMERA N	
			ART UNIT	PAPER NUMBER
			1615	
			MAIL DATE	DELIVERY MODE
			10/04/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)
	10/663,181	WU ET AL.
	Examiner	Art Unit
	Humera N. Sheikh	1615

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
 - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
 - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 24 May 2007.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 25-33 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 25-33 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|--|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____. |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____. | 6) <input type="checkbox"/> Other: _____. |

DETAILED ACTION

Status of the Application

Receipt of the Pre-Appeal Brief request filed 05/24/07 is acknowledged. In view of the pre-appeal brief and Applicant's request for reconsideration, prosecution is hereby reopened.

The following are the new grounds for rejection:

Claims 25-33 are pending in this action. Claims 1-24 have previously been cancelled.

Claims 25-33 are rejected.

* * * * *

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language..

Claims 25-29, 31 and 32 are rejected under 35 U.S.C. 102(e) as being anticipated by Golomb *et al.* (U.S. Pat. No. 6,719,998).

Golomb *et al.* ('998) disclose compositions and methods for the treatment of restenosis (see Abstract); (col. 1, lines 7-10); (col. 7, lines 4-14). The method of treatment of restenosis comprises administering an effective amount of active ingredient (biphosphonates – (BP) or

Art Unit: 1615

pyrophosphate), a complex thereof or a pharmaceutically acceptable salt or ester thereof (col. 2, lines 33-67).

The invention provides for the treatment of in-stent restenosis (col. 3, lines 35-50). Golomb *et al.* teach that the active ingredient may be formulated in a manner allowing its incorporation onto the stent, which will yield administration of said active ingredient directly at the site. The active ingredient may be formulated in that manner, for example, by including it within a coating of the stent. Examples of coating are polymer coatings, e.g., made of polyurethane or a gel (col. 3, lines 47-60).

The compositions may be prepared in various forms such as capsules, tablets, aerosols, solutions, suspensions, or as a coating of a medical device such as a stent (col. 3, line 64 – col. 4, line 9).

In a preferred embodiment of the invention, the active ingredient is formulated into a particulate form. This may be achieved by encapsulating or impregnating the active ingredient into particles, e.g., polymeric particles, lipid vesicles or liposomes (col. 4, lines 9-13). Furthermore, such particles may be particles of polymerized active ingredient (col. 4, lines 13-23).

The compositions may be administered by perivascular delivery by coating of the delivery system on a balloon or stent (col. 6, lines 51-62).

The instant claims are anticipated by Golomb *et al.*

* * * * *

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Claims 25-33 are rejected under 35 U.S.C. 103(a) as being unpatentable over Golomb *et al.* (U.S. Pat. No. 6,719,998).

Golomb *et al.* ('998), as discussed above, teach compositions and methods for the treatment of restenosis (see Abstract); (col. 1, lines 7-10); (col. 7, lines 4-14). The method of treatment of restenosis comprises administering an effective amount of active ingredient (biphosphonates – (BP) or pyrophosphate), a complex thereof or a pharmaceutically acceptable salt or ester thereof (col. 2, lines 33-67).

The invention provides for the treatment of in-stent restenosis (col. 3, lines 35-50). Golomb *et al.* teach that the active ingredient may be formulated in a manner allowing its incorporation onto the stent, which will yield administration of said active ingredient directly at the site. The active ingredient may be formulated in that manner, for example, by including it

Art Unit: 1615

within a coating of the stent. Examples of coating are polymer coatings, e.g., made of polyurethane or a gel (col. 3, lines 47-60).

The compositions may be prepared in various forms such as capsules, tablets, aerosols, solutions, suspensions, or as a coating of a medical device such as a stent (col. 3, line 64 – col. 4, line 9).

In a preferred embodiment of the invention, the active ingredient is formulated into a particulate form. This may be achieved by encapsulating or impregnating the active ingredient into particles, e.g., polymeric particles, lipid vesicles or liposomes (col. 4, lines 9-13). Furthermore, such particles may be particles of polymerized active ingredient (col. 4, lines 13-23).

At column 5, lines 55-58, it is taught that pyrophosphate is preferably formulated and administered in a liposome or a polymeric particle preparation.

The composition of the invention may comprise active ingredient either in their free acid form, complexed with metal cations or may be in the form of salts or esters or they may be polymerized to yield polymers of up to 40 monomers. The salts or polymers may be in a micronized particulate form having a diameter within the range of about 0.01-10 μm (col. 5, line 58 – col. 6, line 4).

Golomb *et al.* teach that the active ingredient may be encapsulated or embedded in inert polymeric particles such as, for example, any of the microcapsules, nanocapsules, nanoparticles, nanospheres, microspheres, microparticles, etc. known in the art. The release of the active ingredient from such particles may be a controlled release, which can result in prolonged and enhanced effect and uptake of the active ingredient (col. 6, lines 18-24).

Art Unit: 1615

Pharmaceutical carriers or diluents are disclosed at col. 6, lines 25-37). The composition used for injection may be selected from emulsions, solutions, suspensions, colloidal solutions containing suitable additives, etc. (col. 6, lines 38-40).

The compositions may be administered by any route, which effectively transports the active compound to the appropriate or desirable site of action. Modes of administration include intravenous, intra-arterial and intramuscularly. Local administration can be carried out by means of a suitable oozing/sweating balloon known in the art (col. 6, lines 41-50).

The compositions may be administered by perivascular delivery by coating of the delivery system on a balloon or stent (col. 6, lines 51-62).

The instant invention, when taken as a whole, would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made, given the teachings of Golomb *et al.*

Response to Arguments

Applicant's arguments with respect to claims 25-33 have been considered but are moot in view of the new ground(s) of rejection.

Conclusion

--No claims are allowed at this time.

Correspondence

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Humera N. Sheikh whose telephone number is (571) 272-0604. The examiner can normally be reached on Monday, Tuesday, Thursday and Friday during regular business hours. (Wednesdays - Telework).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Woodward, can be reached on (571) 272-8373. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have any questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).


HUMERA N SHEIKH
PRIMARY EXAMINER

Art Unit 1615

October 01, 2007

hns